Brief: Imunon Announces Strategic Sale Of Thermodox
Imunon Inc reports results for the quarter ended June 30 - Earnings Summary
Imunon Q2 net loss widens slightly as R&D costs rise
Brief: Imunon Q2 EPS USD -0.54
Imunon Inc expected to post a loss of 93 cents a share - Earnings Preview
Imunon Inc expected to post a loss of 93 cents a share - Earnings Preview
Brief: Imunon Reports Strong Enrollment Momentum In Phase 3 Ovation 3 Trial Of Imnn-001 In Advanced Ovarian Cancer
Brief: Imunon - Jeffrey Church To Retire As Interim CFO Effective July 1, 2026 - SEC Filing
Imunon Q1 net loss widens as R&D spending rises
Brief: Imunon Q1 EPS USD -0.84
Brief: Imunon Reports 2025 Financial Results And Provides Business Update
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
Imunon Rises As Ovarian Cancer Drug Prolongs Survival In Mid: stage study
IMUNON rises on plan to shift resources to ovarian cancer therapy
Brief: Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study
Brief: Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing
Brief: Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer Treatment